Aethlon Medical Australia: New Approach in Cancer Therapy
Aethlon Medical Australia PTY LTD, a subsidiary of Aethlon Medical, is dedicated to advancing innovative therapies for cancer. Our mission is clear: to improve patient outcomes through scientific research and clinical research.
At the core of our efforts is the Hemopurifier®, an investigational medical device designed to remove harmful extracellular vesicles (EVs) and viruses from the bloodstream. These particles released by cells can contribute to the spread of cancers, making them a key target to enhance the effectiveness of existing therapies. By filtering out these harmful elements, the Hemopurifier® may help improve the body’s immune system to attack the cancer.
Advancing Cancer Research
In collaboration with leading medical institutions, Aethlon Medical Australia is conducting a clinical trial focused on cancer patients with solid tumours who have stable or progressive disease despite undergoing anti-PD-1 therapy (such as Keytruda® or Opdivo®). These treatments typically have a response rate of just 20-40% in patients including the very common malignancies melanoma and non-small cell lung cancer (NSCLC).
Clinical trials are now open for enrolment at Royal Adelaide Hospital, Pindara Private Hospital, Gold Coast, and Genesis Care/Royal North Shore Hospital, Sydney.
We aim to build on these results by testing the Hemopurifier® as an adjunctive therapy.
How the Hemopurifier® Works
The Hemopurifier® works by drawing blood from the patient and passing it through a device that separates plasma from cells. A specialised filter containing a plant lectin, Galanthus nivalis agglutinin (GNA), is designed to bind to EVs and viruses, removing them from the bloodstream. The purified blood is then returned to the patient, without the need for plasma replacement. This process has the potential to reduce EV levels and boost anti-tumour immune responses.
The Clinical Trial
Our trial screens patients with stable or progressive disease on monotherapy with pembrolizumab or nivolumab for solid malignancies. Eligible patients will be enrolled in cohorts to receive 1, 2, or 3 Hemopurifier® treatments over a week. An independent Data Safety Monitoring Board (DSMB) will assess safety and feasibility before progressing through each phase. For a complete description of the trial visit Brown, Met al. (2025)
Through this innovative approach, Aethlon Medical Australia aims to improve the lives of patients battling cancer. Clinical trials are now open for enrolment at Royal Adelaide Hospital, Pindara Private Hospital, Gold Coast, and Genesis Care/Royal North Shore Hospital, Sydney.
Source: Sponsored by Aethlon Medical Australia. To find out more about Aethlon and the clinical trial, view Aethlon’s Company Bio page here.
